The city of Chandler, Arizona, currently has 10 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies.
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
NCT06342947
Recruiting
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2024
Locations: Aligos Clinical Study Site 18, Chandler, Arizona
Conditions: NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/22/2024
Locations: Akero Clinical Study Site, Chandler, Arizona
Conditions: NASH/MASH, NAFLD/MASLD
Register for Updates
Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial)
NCT05989711
Recruiting
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2024
Locations: Altimmune Clinical Study Site, Chandler, Arizona
Conditions: Non-Alcoholic Steatohepatitis (NASH)
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2024
Locations: Akero Clinical Study Site, Chandler, Arizona
Conditions: NASH With Fibrosis, MASH With Fibrosis
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Arizona Liver Health - Chandler, Chandler, Arizona
Conditions: NASH, Cirrhosis, Liver
Register for Updates
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT06108219
Recruiting
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/01/2024
Locations: Site #207, Chandler, Arizona
Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: The Institute For Liver Health - Chandler, Chandler, Arizona
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
NCT04880031
Recruiting
This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/04/2024
Locations: Arizona Liver Health, Chandler, Arizona
Conditions: Nonalcoholic Steatohepatitis (NASH)
Register for Updates
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
NCT05117489
Recruiting
This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/28/2023
Locations: Site 207, Chandler, Arizona
Conditions: Nonalcoholic Steatohepatitis (NASH)
Register for Updates
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
NCT04054310
Recruiting
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 & F≥2 from those without.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/07/2023
Locations: Arizona Liver Health, Chandler, Arizona
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates